Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000933 · ClinicalTrials.gov registry record

Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048

A clinical trial of HIV Infections and Pneumococcal Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
326
Enrollment target
15
Study locations

NCT00000933: Completed study of HIV Infections and Pneumococcal Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00000933 is a study of HIV Infections and Pneumococcal Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 326 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (27% lower). The trial reports 15 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000933, a study of HIV Infections and Pneumococcal Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
326 participants
Enrollment target
15
Study locations

Study Summary

Some people who have taken azithromycin to prevent MAC (Mycobacterium avium Complex, a bacterial infection common in HIV-infected persons) have been found to carry antibiotic-resistant bacteria (germs that grow despite the presence of drugs used to kill them). The purpose of this study is to see if people who take azithromycin carry more antibiotic-resistant bacteria than people who have chosen to delay MAC preventive therapy. When bacteria like Streptococcus (a type of bacteria that causes pneumonia and meningitis) are frequently exposed to antibiotics, the bacteria can become resistant to the drugs. MAC preventive therapy uses antibiotics, but this can make it difficult to treat other infections caused by bacteria that have become resistant in HIV-infected persons. If MAC preventive therapy is delayed, Streptococcus in the body may be less likely to develop resistance. Therefore, if the patient does get a Streptococcus infection, it will be easier to treat because it is not resistant to the antibiotics.

Conditions Studied

HIV Infections Pneumococcal Infections Mycobacterium Avium-Intracellulare Infection

Study Locations (15)

Michigan

  • Wayne State Univ - WSU/DMC / Univ Hlth Ctr - Detroit
  • Henry Ford Hosp - Detroit

New Jersey

  • Southern New Jersey AIDS Cln Trials / Dept of Med - Camden
  • North Jersey Community Research Initiative - Newark

California

  • Community Consortium / UCSF - San Francisco

Colorado

  • Denver CPCRA / Denver Public Hlth - Denver

District of Columbia

  • Washington Reg AIDS Prog / Dept of Infect Dis - Washington D.C.

Georgia

  • AIDS Research Consortium of Atlanta - Atlanta

Illinois

  • AIDS Research Alliance - Chicago - Chicago

Louisiana

  • Louisiana Comm AIDS Rsch Prog / Tulane Univ Med - New Orleans

Trial Details

FieldValue
Enrollment Target 326 participants
Est. Completion 2000-07
National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

What the finished NCT00000933 record still lists

NCT00000933 is an observational study that tracks outcomes without assigning an intervention. The registered 326 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (27% lower).

The record links to 3 conditions, with HIV Infections appearing as the primary indexed condition, and to 0 interventions.

NCT00000933 lists 15 locations in 13 states (Michigan, New Jersey, California).

Frequently Asked Questions

What is clinical trial NCT00000933 about?

NCT00000933 is a clinical study titled "Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048". Some people who have taken azithromycin to prevent MAC (Mycobacterium avium Complex, a bacterial infection common in HIV-infected persons) have been found to carry antibiotic-resistant bacteria (germs that grow despite the presence of drugs used to kill them). The purpose of this study is to see if ...

What is the current status of trial NCT00000933?

This trial is currently completed. The enrollment target is 326 participants. Estimated completion is 2000-07.

What conditions does trial NCT00000933 study?

This clinical trial studies the following conditions: HIV Infections, Pneumococcal Infections, Mycobacterium Avium-Intracellulare Infection.

Who is sponsoring clinical trial NCT00000933?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000933 being conducted?

This trial has 15 study locations across California, Colorado, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00000933's enrollment target sits among peer trials

326 108th of 542 higher than 435 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06410144 · 326 participants · NA

    Chronic Kidney Disease-Education (CKD-EDU)

  • NCT06586619 · 326 participants · NA

    A Remotely Delivered Tai Chi/Qigong Intervention for Older People Living With HIV

  • NCT07040566 · 326 participants · Phase 2

    A Trial of Varenicline for E-cigarette Cessation

  • NCT07165860 · 326 participants · NA

    Clinical Trial to Reduce Perinatal Intimate Partner Violence

Related registry views

Source: ClinicalTrials.gov NCT00000933, the US trial registry maintained by the National Library of Medicine. NCT00000933 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.